Startup · $3m raised
Developing a biologic therapy for Duchenne Muscular Dystrophy that promotes muscle regeneration with minimal fibrosis
Melbourne, VIC
Programs: Breakthrough Victoria (University Innovation Platform) · Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Myostellar raised.
| Investor | Rounds | Invested |
|---|---|---|
| Monash Ventures Pre-Seed Fund | Pre-seed | - |
| Monash Ventures | Pre-seed | - |
| Monash University | Pre-seed · Pre-seed | $375,000 |
| Breakthrough Victoria | Pre-seed · Pre-seed · Accelerator | $375,000 |
| Brandon BioCatalyst | Accelerator | - |
Companies Myostellar acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Bo Yun | CCO Dr | Breakthrough Victoria |
| Prof Mikaël Martino | Co-founder Prof. | Breakthrough Victoria |
| Prof Peter Currie | Co-founder Professor | Breakthrough Victoria (4 Aug 2025), SmartCompany, Breakthrough Victoria (1 Aug 2025) |
Stories naming Myostellar. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Two Victorian backers put a combined $2.25 million into three university spinouts pursuing biologics, antibody drugs and delivery devices, launching a new $15 million pre-seed vehicle.
Also @AuManufacturing
Weekly roundup: Breakthrough Victoria and Monash University co-invest $2.25 million across three university healthtech spinouts, while Blackbird backs Hall, which helps businesses win visibility on AI platforms, with $2 million pre-seed.
Also Startup Daily
Breakthrough Victoria and Monash University put joint pre-seed backing into three life-sciences spinouts and launched the $15m Monash Ventures pre-seed fund, part of a $100m platform commercialising Victorian university research.
The investor's site reports a joint pre-seed investment with Monash University totalling $2.25 million across three health startups, and the launch of Monash Ventures' $15 million pre-seed fund for research commercialisation.
Also Breakthrough Victoria·SmartCompany·@AuManufacturing·@AuManufacturing
Brandon BioCatalyst's CUREator incubator has granted an extra $1.865m across four Australian biotechs working on antibiotic prescribing, schizophrenia, muscular dystrophy and autoimmune therapies, on top of their initial awards.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.